SEARCH

SEARCH BY CITATION

References

  • 1.
    2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;53:13431382.
  • 2.
    Opie LH, Commerford PJ, Gersh BJ, et al. Controversies in ventricular remodeling. Lancet. 2006;367:356367.
  • 3.
    Douglas PS, Morrow R, Ioli A, et al. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1989;13:311315.
  • 4.
    Rumberger JA, Behrenbeck T, Breen JR, et al. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol. 1993;21:673682.
  • 5.
    Udelson JE, Konstam MA. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail. 2002;8:S465S471.
  • 6.
    Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in hear failure. Circulation. 1993;87(suppl VI):VI5V16.
  • 7.
    Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation. 1995;91:25732581.
  • 8.
    Waagstein F, Stromblad O, Andersson B, et al. Increased exercise ejection fraction and reversed remodelling after long-term treatment with metoprolol in congestive heart failure: a randomized, stratified, double-blind, placebo-controlled trial in mild to moderate heart failure due to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2003;5:679691.
  • 9.
    Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise capacity in chronic heart failure patients. J Am Coll Cardiol. 2002;40:304310.
  • 10.
    Yu C-M, Bleeker GB, Fung JW-H, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. Circulation. 2005;112:15801586.
  • 11.
    Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantification of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358367.
  • 12.
    Oh JK, Appleton CP, Hatle LK, et al. The noninvasive assessment of left ventricular diastolic function with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 1997;10: 246270.
  • 13.
    Greenberg BH. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials. J Card Fail. 2002; 8(suppl):S486S490.
  • 14.
    Takano H, Hasegawa H, Nagai T, et al. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies. Int Medicine. 2003;42:465469.
  • 15.
    Armstrong PW. Left ventricular dysfunction: causes, natu- ral history and hopes for reversal. Heart. 2000;84(suppl I): I15I17.
  • 16.
    Yndestad A, Damas JK, Oie E, et al. Systemic inflammation in heart failure—the whys and wherefores. Heart Fail Rev. 2006; 11:8392.
  • 17.
    Cicoira M, Rossi A, Bonapace S, et al. ACE gene insertion/ deletion polymorphism and response to spironolactone administration in chronic heart failure patients. Am J Med. 2004;116; 657661.
  • 18.
    Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669677.
  • 19.
    Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. 1999;354:912.
  • 20.
    Cohn J, Tognoni G. Randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:16671675.
  • 21.
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709717.
  • 22.
    Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:20012007.
  • 23.
    A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994;90:17651773.
  • 24.
    Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:13851390.
  • 25.
    Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2001;15:910.
  • 26.
    Colucci WS, Kolias TJ, Adams KF, et al; REVERT Study Group. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction—the Reversal of Ventricular Remodeling with Toprol-XL (REVERT) Trial. Circulation. 2007;116:4956.
  • 27.
    De Groote P, Delour P, Mouquet F, et al. The effects of β-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J. 2007;154:589595.
  • 28.
    Kramer DG, Tikalinos TA, Kent DM, et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010;56:392406.